person · Reporting owner

Ausiello Dennis A

Disclosed activity across 4 companies

Tapewire entity: 16093
SEC CIK: 0001381994

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	May 20, 2026	May 22, 2026
PFIZER INCPFE · Entity 2863	Director	April 26, 2018	April 30, 2018
Rani Therapeutics Holdings, Inc.RANI · Entity 6642	Director	May 28, 2026	June 01, 2026
Seres Therapeutics, Inc.MCRB · Entity 7191	Director	July 08, 2026	July 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,582	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 671 · Balance 1,582 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20	Direct	1,441	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Common StockSEC Table I · non-derivative	Indirectby Trust	3,500	Reported balance Holding disclosure · report date 2026-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,500 F2: The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2: The shares of ALNY common stock are held in a trust, of which the reporting person's spouse is the trustee.

F3: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

PFIZER INC

Report date April 26, 2018 · Filed April 30, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock UnitsSEC Table II · derivative / convertible security	Direct	47,345.774	Reported balance After 2018-04-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-04-26 · Grant · Acquired 5,223.881 · Balance 47,345.774 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.

F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

Rani Therapeutics Holdings, Inc.

Report date May 28, 2026 · Filed June 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-27	Direct	123,600	Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 123,600 · Balance 123,600 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Seres Therapeutics, Inc.

Report date July 08, 2026 · Filed July 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07	Direct	6,500	Reported balance After 2026-07-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 16, 2024 Filed May 20, 2024 20:03 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	5,228	$0.00 Strike: $151.22	$0.00	Disclosure SEC source: 0001735276-24-000046 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
April 04, 2024 Filed Apr 8, 2024 20:45 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $0.76	$0.00	Disclosure SEC source: 0000950170-24-042656 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-04-03 F1 · derivative.exercise_date: The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders. Read SEC document
December 16, 2023 Filed Dec 19, 2023 21:05 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	GrantStock Option (Right to Buy) · Derivative	15,423	Not disclosed Strike: $2.84	Not disclosed	Disclosure SEC source: 0000950170-23-071471 · ownership.xml · derivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,423 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021. Read SEC document
December 16, 2023 Filed Dec 19, 2023 21:05 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	Disposition to issuerStock Option (Right to Buy) · Derivative	15,423	Not disclosed Strike: $9.44	Not disclosed	Disclosure SEC source: 0000950170-23-071471 · ownership.xml · derivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,894 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F3 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021. F3 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document
December 16, 2023 Filed Dec 19, 2023 21:05 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	GrantStock Option (Right to Buy) · Derivative	101,276	Not disclosed Strike: $2.84	Not disclosed	Disclosure SEC source: 0000950170-23-071471 · ownership.xml · derivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document
December 16, 2023 Filed Dec 19, 2023 21:05 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	Disposition to issuerStock Option (Right to Buy) · Derivative	101,276	Not disclosed Strike: $4.11	Not disclosed	Disclosure SEC source: 0000950170-23-071471 · ownership.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document
June 22, 2023 Filed Jun 23, 2023 21:29 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $5.46	$0.00	Disclosure SEC source: 0000899243-23-016406 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. Read SEC document
May 25, 2023 Filed May 31, 2023 00:04 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	GrantStock Option (Right to Buy) · Derivative	101,276	$0.00 Strike: $4.11	$0.00	Disclosure SEC source: 0001209191-23-033043 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document
May 18, 2023 Filed May 19, 2023 20:04 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	3,454	$0.00 Strike: $189.87	$0.00	Disclosure SEC source: 0001735276-23-000062 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:11 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionRestricted Stock Units · Derivative	136	$0.00	$0.00	Disclosure SEC source: 0001735276-23-000015 · edgardoc.xml · derivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F3 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date. Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:11 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	136	$0.00	$0.00	Disclosure SEC source: 0001735276-23-000015 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 21, 2022 Filed Nov 23, 2022 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	11,250	$0.00 Strike: $71.99	$0.00	Disclosure SEC source: 0001735276-22-000076 · edgardoc.xml · derivative · entry 6 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2022. Read SEC document
November 21, 2022 Filed Nov 23, 2022 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	11,250	$0.00 Strike: $70.20	$0.00	Disclosure SEC source: 0001735276-22-000076 · edgardoc.xml · derivative · entry 5 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2026-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2022. Read SEC document
November 21, 2022 Filed Nov 23, 2022 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	22,500	$220.00	$4,950,000.00	Disclosure SEC source: 0001735276-22-000076 · edgardoc.xml · nonDerivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2022. Read SEC document
November 21, 2022 Filed Nov 23, 2022 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	11,250	$71.99	$809,887.50	Disclosure SEC source: 0001735276-22-000076 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2022. Read SEC document
November 21, 2022 Filed Nov 23, 2022 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	11,250	$70.20	$789,750.00	Disclosure SEC source: 0001735276-22-000076 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2022. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:31 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $3.22	$0.00	Disclosure SEC source: 0000899243-22-023974 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document
May 25, 2022 Filed May 27, 2022 12:30 UTC	Rani Therapeutics Holdings, Inc. RANI · Entity 6642	GrantStock Option (Right to Buy) · Derivative	41,416	$0.00 Strike: $10.89	$0.00	Disclosure SEC source: 0000899243-22-019860 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,416 Underlying: Class A Common Stock · 41,416 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document
May 18, 2022 Filed May 20, 2022 20:06 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	5,153	$0.00 Strike: $128.31	$0.00	Disclosure SEC source: 0001735276-22-000050 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
February 23, 2022 Filed Feb 25, 2022 21:10 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantRestricted Stock Units · Derivative	136	$0.00	$0.00	Disclosure SEC source: 0001735276-22-000031 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
July 15, 2021 Filed Jul 19, 2021 20:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,032	$0.00 Strike: $171.95	$0.00	Disclosure SEC source: 0001735276-21-000067 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:30 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	23,000	$0.00 Strike: $19.74	$0.00	Disclosure SEC source: 0000899243-21-024997 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:52 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,581	$0.00 Strike: $148.77	$0.00	Disclosure SEC source: 0001735276-20-000080 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document
June 18, 2020 Filed Jun 22, 2020 20:15 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $4.40	$0.00	Disclosure SEC source: 0000899243-20-017361 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document
July 01, 2019 Filed Jul 2, 2019 20:03 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $72.01	$0.00	Disclosure SEC source: 0001735276-19-000059 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document
June 13, 2019 Filed Jun 14, 2019 20:09 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $2.83	$0.00	Disclosure SEC source: 0000899243-19-017012 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. Read SEC document
June 26, 2018 Filed Jun 28, 2018 01:02 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $9.09	$0.00	Disclosure SEC source: 0000899243-18-018512 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document
June 20, 2018 Filed Jun 22, 2018 20:17 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $105.26	$0.00	Disclosure SEC source: 0001735276-18-000026 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document
April 26, 2018 Filed Apr 30, 2018 17:30 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,223.881	$36.85	$192,500.01	Disclosure SEC source: 0001225208-18-008213 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,345.774 Underlying: Common Stock · 5,223.881 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:40 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	2,117	$0.00 Strike: $63.86	$0.00	Disclosure SEC source: 0001553878-18-000022 · edgardoc.xml · derivative · entry 6 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,117 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:40 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $59.25	$0.00	Disclosure SEC source: 0001553878-18-000022 · edgardoc.xml · derivative · entry 5 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:40 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	17,117	$150.00	$2,567,550.00	Disclosure SEC source: 0001553878-18-000022 · edgardoc.xml · nonDerivative · entry 3 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:40 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	15,000	$59.25	$888,750.00	Disclosure SEC source: 0001553878-18-000022 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
March 13, 2018 Filed Mar 14, 2018 23:40 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	2,117	$63.86	$135,191.62	Disclosure SEC source: 0001553878-18-000022 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
November 02, 2017 Filed Nov 4, 2017 00:14 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $30.09	$0.00	Disclosure SEC source: 0001553878-17-000057 · edgardoc.xml · derivative · entry 4 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. F3 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document
November 02, 2017 Filed Nov 4, 2017 00:14 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	20,000	$130.00	$2,600,000.00	Disclosure SEC source: 0001553878-17-000057 · edgardoc.xml · nonDerivative · entry 2 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
November 02, 2017 Filed Nov 4, 2017 00:14 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	20,000	$30.09	$601,800.00	Disclosure SEC source: 0001553878-17-000057 · edgardoc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2017. Read SEC document
June 20, 2017 Filed Jun 21, 2017 21:10 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $11.21	$0.00	Disclosure SEC source: 0000899243-17-016855 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document
June 02, 2017 Filed Jun 6, 2017 20:53 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	11,250	$0.00 Strike: $71.99	$0.00	Disclosure SEC source: 0001553878-17-000018 · edgardoc.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document
April 27, 2017 Filed Apr 28, 2017 17:38 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,537.507	$33.86	$187,499.99	Disclosure SEC source: 0001225208-17-008575 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,121.892 Underlying: Common Stock · 5,537.507 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document
April 28, 2016 Filed Apr 29, 2016 22:22 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,697.356	$32.91	$187,499.99	Disclosure SEC source: 0001225208-16-032024 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,584.385 Underlying: Common Stock · 5,697.356 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document
April 23, 2015 Filed Apr 24, 2015 18:00 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	4,595.588	$35.36	$162,499.99	Disclosure SEC source: 0001225208-15-010347 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,887.024 Underlying: Common Stock · 4,595.588 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document
April 24, 2014 Filed Apr 28, 2014 17:29 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,291.436	$30.71	$162,500.00	Disclosure SEC source: 0001225208-14-011189 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,291.436 Underlying: Common Stock · 5,291.436 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document
April 22, 2010 Filed Apr 26, 2010 14:09 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,500	$0.00	$0.00	Disclosure SEC source: 0001225208-10-010899 · doc4.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document
April 22, 2010 Filed Jun 1, 2010 20:59 UTC Amendment	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	0	$0.00	$0.00	Disclosure SEC source: 0001225208-10-014338 · doc4a.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 0 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · kind: On April 26, 2010, the reporting person inadvertently filed a Form 4 reporting the acquisition of 5,500 Pfizer phantom stock units that did not in fact occur. As of April 22, 2010, the reporting person owned 21, 000 Pfizer phantom stock units. F2 · derivative.exercise_date: On April 26, 2010, the reporting person inadvertently filed a Form 4 reporting the acquisition of 5,500 Pfizer phantom stock units that did not in fact occur. As of April 22, 2010, the reporting person owned 21, 000 Pfizer phantom stock units. F2 · derivative.expiration_date: On April 26, 2010, the reporting person inadvertently filed a Form 4 reporting the acquisition of 5,500 Pfizer phantom stock units that did not in fact occur. As of April 22, 2010, the reporting person owned 21, 000 Pfizer phantom stock units. F2 · balance_after: On April 26, 2010, the reporting person inadvertently filed a Form 4 reporting the acquisition of 5,500 Pfizer phantom stock units that did not in fact occur. As of April 22, 2010, the reporting person owned 21, 000 Pfizer phantom stock units. Read SEC document
October 15, 2009 Filed Oct 19, 2009 20:13 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	887	Not disclosed	Not disclosed	Disclosure SEC source: 0000078003-09-000231 · primary_doc.xml · nonDerivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 887 F1 · price: Received (together with $33.00 in cash for each share of Wyeth common stock) in exchange for 900 shares of Wyeth common stock in connection with the acquisition of Wyeth by Pfizer Inc. (the "Acquisition"). On the closing date of the Acquisition, the closing price of Wyeth's common stock was $50.39 per share. F2 · ownership.nature: I hereby disclaim beneficial ownership of all shares held by members of my family. Read SEC document
April 23, 2009 Filed Apr 24, 2009 21:11 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,500	$0.00	$0.00	Disclosure SEC source: 0000078003-09-000078 · aus2014.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document
April 24, 2008 Filed Apr 25, 2008 17:26 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,500	$0.00	$0.00	Disclosure SEC source: 0000078003-08-000073 · aus1725.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document
April 26, 2007 Filed Apr 30, 2007 18:55 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0000078003-07-000082 · aus1481.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,055 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document
December 01, 2006 Filed Dec 4, 2006 19:52 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units · Derivative	5,000	$0.00	$0.00	Disclosure SEC source: 0000078003-06-000333 · aus1389.xml · derivative · entry 1 Ausiello Dennis A · CIK 0001381994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units are settled in cash following the reporting person's retirement from the Board of Directors. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.